News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,191 Results
Type
Article (13850)
Company Profile (101)
Press Release (253240)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88344)
Career Advice (465)
Deals (15406)
Drug Delivery (67)
Drug Development (36713)
Employer Resources (49)
FDA (6309)
Job Trends (6210)
News (150700)
Policy (14084)
Tag
Academia (446)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23311)
ALS (37)
Alzheimer's disease (395)
Antibody-drug conjugate (ADC) (42)
Approvals (6348)
Artificial intelligence (113)
Autoimmune disease (9)
Automation (4)
Bankruptcy (150)
Best Places to Work (4377)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (645)
Cardiovascular disease (73)
Career advice (409)
Career pathing (12)
CAR-T (22)
Cell therapy (89)
Cervical cancer (4)
Clinical research (31036)
Collaboration (355)
Compensation (157)
Complete response letters (17)
COVID-19 (762)
CRISPR (22)
C-suite (128)
Cystic fibrosis (38)
Data (675)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1363)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (62)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32385)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37766)
Executive appointments (400)
FDA (6753)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (220)
Gene editing (40)
Generative AI (10)
Gene therapy (101)
GLP-1 (351)
Government (1306)
Grass and pollen (3)
Guidances (21)
Healthcare (3632)
Huntington's disease (4)
IgA nephropathy (14)
Immunology and inflammation (35)
Indications (15)
Infectious disease (799)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5924)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (182)
Leadership (4)
Legal (3435)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (162)
MASH (33)
Medical device (1297)
Medtech (1299)
Mergers & acquisitions (9692)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (585)
NextGen: Class of 2025 (1587)
Non-profit (597)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (53)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (30)
Peanut (10)
People (29024)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8089)
Phase II (13136)
Phase III (11771)
Pipeline (470)
Policy (72)
Postmarket research (1403)
Preclinical (3242)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (121)
Rare diseases (171)
Real estate (2641)
Recruiting (17)
Regulatory (10176)
Reports (14)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1637)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (31)
The Weekly (30)
Vaccines (161)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (59)
Last 7 days (265)
Last 30 days (914)
Last 365 days (11837)
2025 (3926)
2024 (12577)
2023 (14350)
2022 (19685)
2021 (20352)
2020 (19167)
2019 (14947)
2018 (11756)
2017 (13927)
2016 (13159)
2015 (15493)
2014 (12432)
2013 (10626)
2012 (11419)
2011 (11964)
2010 (10935)
Location
Africa (314)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20173)
Australia (2625)
California (1797)
Canada (933)
China (249)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39739)
Florida (340)
Georgia (39)
Idaho (9)
Illinois (202)
India (16)
Indiana (136)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (271)
Massachusetts (1547)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (789)
New Mexico (7)
New York (531)
North Carolina (405)
North Dakota (2)
Northern California (739)
Ohio (52)
Oklahoma (4)
Oregon (16)
Pennsylvania (460)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (753)
Tennessee (34)
Texas (236)
United States (7487)
Utah (34)
Virginia (77)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
267,191 Results for "amring pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund
January 29, 2025
·
2 min read
Business
Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR)
Er-Kim Pharmaceuticals joins the industry to collaborate on the prevention of antimicrobial resistance (AMR) in support of World AMR Awareness Week, a global campaign to promote understanding of antimicrobial resistance (AMR).
November 24, 2023
·
3 min read
Press Releases
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
March 11, 2025
·
8 min read
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
MeMed Expands Advisory Board with Key Leaders to Advance Host-Response Diagnostics for Sepsis and AMR
January 9, 2025
·
3 min read
Press Releases
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
October 8, 2024
·
9 min read
Pharm Country
Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
Elion Therapeutics announced today it has closed a $81 million Series B funding round led by Deerfield Management (“Deerfield”) and the AMR Action Fund. Additional investors include Illinois Ventures.
June 17, 2024
·
4 min read
Deals
Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).
December 18, 2023
·
5 min read
Business
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair
Amring Pharmaceuticals Inc. announced that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board which includes Richard Lindstrom, MD, Vance Thompson, MD, Preeya Gupta, MD, Paul Karpecki, OD, Lisa Nijm, MD, JD, and Selina McGee, OD.
February 26, 2024
·
5 min read
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme
BioVersys AG announced that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease in people with cystic fibrosis.
June 4, 2024
·
10 min read
1 of 26,720
Next
